Skip to main content
. 2022 Oct 21;77(2):1129–1148. doi: 10.1007/s11696-022-02528-y

Fig. 2.

Fig. 2

Imatinib interactions with binding residues of (a) RdRp (6m71), (b) Mpro (6lu7), (c) ACE2 receptor (6M0J), (d) SARS-CoV-2 spike glycoprotein (6M0J), and (e) TMPRSS2 (7MEQ). The 3D structures of these interactions are shown in Fig. S6